Drug Profile


Alternative Names: h1F6; SGN-70

Latest Information Update: 09 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD70 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Cancer; Inflammation; Plaque psoriasis

Most Recent Events

  • 05 Aug 2011 Discontinued - Phase-I for Plaque psoriasis in Switzerland (IV)
  • 05 Aug 2011 Discontinued - Preclinical for Autoimmune disorders in USA (Parenteral)
  • 05 Aug 2011 Discontinued - Preclinical for Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top